Overview

Peptide-specific Vaccination in HLA-A*02 Positive Patients With Biochemical Recurrence After Radical Prostatectomy

Status:
Unknown status

Trial end date:
2017-10-01

Target enrollment:

Participant gender:

Summary

The study evaluates the prostate-specific antigen (PSA) response in HLA-A*02 positive patients with biochemical recurrence after radical prostatectomy treated with a prostate-specific peptide vaccine in combination with different immune-adjuvants.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

University Hospital Tuebingen

Treatments:

Freund's Adjuvant
Imiquimod
Molgramostim
Protamines
Sargramostim
Vaccines